Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Cortamine PTM (trimeprazine with prednisolone) Tablets
Medication labelWhy this: Advisory · dailymed-animal
1. Antipruritic: Cortamine P™ (trimeprazine with prednisolone) is recommended for the relief of itching regardless of cause. Its usefulness has been demonstrated for the relief of itching and the reduction of inflammation commonly associated with most skin disorders of dogs such as the eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular, and nonspecific). It often relieves pruritus which does not respond to other therapy. With any pruritus treatment, the cause should be determined and corrected; otherwise, signs are likely to recur following discontinuance of therapy. 2. Antitussive: Cortamine P™ (trimeprazine with prednisolone) has been found to be effective therapy and adjunctive therapy in various cough conditions of dogs. Therefore, in addition to its antipruritic action, Cortamine P™ (trimeprazine with prednisolone) is recommended for the treatment of "kennel cough" or tracheobronchitis, bronchitis including all allergic bronchitis, and infections and coughs of nonspecific origin. (Coughs due to cardiac insufficiencies would not be expected to respond to Cortamine P™ (trimeprazine with prednisolone) therapy.) As with any antitussive treatment, the etiology of the cough should be determined and eliminated if possible. Otherwise, symptoms are likely to recur following discontinuance of therapy. Note: Cortamine P™ (trimeprazine with prednisolone) may be administered to animals suffering from acute or chronic bacterial infections provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents.
- generic_name
- trimeprazine with prednisolone
- product_names
- trimeprazine with prednisolone
- ndc
- 86136-126, 86136-126-36, 86136-126-65
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en